Researchers at Huntsman Cancer Institute have identified a specific gene-regulating protein complex to target in the treatment of synovial sarcoma. The study provides new understanding of how the disease develops and spreads, offering potential breakthroughs in diagnosis and therapy.
A new study published in the Journal of Clinical Oncology reports findings on Huntsman at Home, a cancer hospital-at-home model that demonstrates lower costs and better outcomes for patients. The study found that participants had 55% fewer hospitalizations and 47% lower healthcare costs compared to those who did not participate.
Researchers at Huntsman Cancer Institute discovered that nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in how immune cells fight melanoma tumors. The study found that disrupting the NAMPT pathway impairs antitumor function, and novel therapies targeting this pathway may lead to improved outcomes for patients.
Utah researchers identify mutation hotspots and find that approximately 2% of healthy participants had the same mutations as cancer patients. This study provides new insights into the development of blood cancers and may help identify people at risk.
Researchers at Huntsman Cancer Institute have identified a potential drug combination to treat uveal melanoma by targeting genes GNAQ and GNA11. The study showed that using trametinib and hydroxychloroquine together led to more cell deaths than the drugs alone.
Researchers at Huntsman Cancer Institute discovered that chromatin remodeling machines have a motor-like component that drives the machine along DNA, disrupting nucleosome beads. The team found cancer-causing mutations in an area of the hub regulating motor activity, leading to improper gene expression and cancer.
African American men have lowest five-year survival rate for colorectal cancer due to low adherence to recommended early detection screening. Researchers recommend focusing interventions on recruiting men from this population and conducting studies in non-traditional health care settings.
Researchers at Huntsman Cancer Institute discovered that HIF-1α is linked to aggressive tumors, metastasis, and poor patient survival, while HIF-2α is associated with less aggressive tumors and better outcomes. The study suggests a potential new paradigm for understanding kidney cancer.
Researchers at Huntsman Cancer Institute develop new models to study molecular characteristics of lung and pancreas tumors driven by NTRK1 mutations. The findings aim to identify effective treatments for patients with NTRK1-driven cancers, which have proven resistant to current therapies.
Researchers found that factors produced by bone marrow support cells helped leukemia cells survive treatment with quizartinib, a type of tyrosine kinase inhibitor. However, when quizartinib was combined with another TKI called dasatinib, the alternative survival pathways were shut down, leading to more effective leukemia cell death.
A consensus statement evaluates the use of prognostic genetic expression profile testing in melanoma, cautioning against routine use due to limitations. The statement aims to assist clinicians in determining when and how gene expression profiling should be adopted in clinical practice.
Scientists have discovered that a steroidal sex hormone, ecdysone, drastically alters intestinal stem cell behavior, affecting gut growth and function. The study found that ecdysone stimulates stem cell growth and causes the gut to grow in size, leading to changes in its structure and function.
Scientists have made a breakthrough discovery in understanding small cell lung cancer, finding that it can change and adapt to evade treatments. The study suggests that the tumor is like a 'moving target' that requires multiple treatments to be effective.
Researchers found that patients in Huntsman at Home had reduced hospitalizations, emergency department visits, and cumulative charges compared to controls. The study demonstrated strong evidence for the care model, showing improved patient outcomes while improving value.
Scientists at Huntsman Cancer Institute have discovered the protein LEM2 plays two vital roles during cell division: sealing damaged DNA and recruiting factors that disassemble fibers separating DNA sets. This process may be critical for understanding cancer development and progression.
Researchers at Huntsman Cancer Institute have identified a critical protein called ETV4 that promotes estrogen signaling in endometrial cancer cells. By removing ETV4, tumor growth can be significantly reduced, offering new avenues for treatment development.
Researchers at Huntsman Cancer Institute developed a novel CAR T cell therapy targeting CD229, a molecule present on cancer cells and stem cells in patients with multiple myeloma. Laboratory tests showed promising results, including the ability to kill mature multiple myeloma cells and myeloma stem cells.
Researchers analyzed genome-scale data from male adolescents to understand changes in stem cells during puberty. They found that testosterone is crucial for maintaining mature testis development, and disruptions can lead to infertility and increased risk of testicular cancer.
Researchers have developed a high-resolution visual map of the RSC complex, a crucial regulator of chromosome structure and gene expression. This study provides new insights into how RSC-like complexes are involved in cancer development and has implications for understanding chromosomal genes in healthy and cancer cells.
Scientists at Huntsman Cancer Institute have discovered a way for cells to override genetic changes, potentially leading to more effective pancreatic cancer treatment. The study found that introducing PTF1A into normal cells prevented the formation of cancer cells and even reversed early-stage cancer cells back to healthy pancreas cells.
A new study found that genetic testing motivates people at risk of developing melanoma to change their behavior, including reducing sun exposure. Participants who received genetic counseling showed sustained reductions in UV radiation exposure and lighter skin pigmentation over time.
Researchers at Huntsman Cancer Institute discovered a new experimental drug, selinexor, which may block a crucial survival pathway exploited by myelofibrosis cells. A clinical trial has been designed to examine the drug's effectiveness in patients with myelofibrosis.
Researchers developed a biomarker test to predict disease-free survival and recurrence risk in patients with triple-negative breast cancer. The test uses formalin-fixed, paraffin-embedded tissues and has shown promise in predicting patient outcomes.
A phase III international clinical trial found that treatment with apalutamide significantly improved overall survival by 33% compared to standard-of-care therapy. The study also showed apalutamide delayed disease progression, increasing the time until chemotherapy was needed.
Researchers analyzed over 3,500 tumor samples to identify genomic changes that inform targeted treatment strategies for men with advanced prostate cancers. The study found that more than half of patients have characteristics that suggest they are suitable for targeted therapies.
A study found that poor air quality significantly increases the risk of hospitalizations for respiratory issues in young cancer survivors, particularly those who received chemotherapy. The researchers tracked nearly 4,000 survivors and found that even low levels of PM2.5 can contribute to respiratory problems.
Researchers at Huntsman Cancer Institute discovered a combination drug therapy that may effectively combat the disease. The study, led by Conan Kinsey and Martin McMahon, found a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer.
A new study published in Pediatric Blood and Cancer found that early cancer surveillance in patients with Li-Fraumeni Syndrome is cost-effective, resulting in additional years of life. The research showed a significant increase in life expectancy for high-risk patients, with healthcare costs estimated at $17,000 per year gained.
A novel tool has been developed to identify genetic changes in Lynch syndrome genes associated with disease symptoms. The tool, combining laboratory test results with computer-based modeling and clinical data, achieves an accuracy of about 97 percent, making it suitable for clinical use.
The Utah Cancer Registry will continue to collect high-quality data on cancer patients in Utah for the next 10 years. The funding will support research aimed at preventing cancer and prolonging lives of those diagnosed with the disease.
Researchers at Huntsman Cancer Institute discovered that different types of lung tumors recruit distinct immune cells, which can help or hinder tumor growth. The study found that high levels of neutrophils are associated with a bad response to immunotherapy, suggesting them as a potential target for new treatments.
Researchers have identified NOTCH 1 as a key player in the metastasis of medulloblastoma, a type of pediatric brain cancer. The study also suggests that targeting this protein could lead to a more effective treatment option with fewer side effects.
Scientists at Huntsman Cancer Institute have generated a comprehensive molecular map of genes that control breast tissue formation, providing new insights into the development of breast cancer. The study identifies hundreds of potentially critical genes for further research as regulators of normal and cancerous development.
The center aims to study ways to reduce cancer risk among underserved individuals and improve outcomes among those with a diagnosis, utilizing tools like mobile health technology.
A recent study published in Cell Reports has revealed that mutant Isocitrate dehydrogenase 1 (IDH1) drives glioma development by cooperating with multiple mutations and events in brain tumor cells. This breakthrough discovery provides substantial evidence for the functional role of mutant IDH1 in tumorigenesis.
Research at Huntsman Cancer Institute found that estrogen and glucocorticoid receptors work together to promote more aggressive endometrial cancers. The study suggests that corticosteroids, a stress hormone, can make the uterine lining stop growing but may also contribute to tumor growth when combined with high estrogen levels.